Screener
Theravance Biopharma TBPH Q2 2026 earnings
Reported August 10, 2026 · Before market open
Revenue$20.7MMiss by $1.8M
EPS-$0.11Miss by $0.18
Revenue estimate$22.5M
EPS estimate$0.07
“During the second quarter, we entered into a definitive agreement to be acquired by Zymeworks, marking the culmination of a comprehensive strategic review process and what we believe achieves the greatest value for Theravance Biopharma shareholders, At the same time, YUPELRI® delivered another strong quarter, underscoring the durability and value of our core commercial asset and the continued execution of our collaboration with Viatris. We continued to execute well against our restructuring plan and expect to close the Zymeworks transaction in the second half of 2026 subject to shareholder approval and customary closing conditions.”
Next report
Nov 10, 2026 (in 2 months)Revenue estimate$22.0M
EPS estimate$0.24
Financials
Q2 2026Valuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Theravance Biopharma report Q2 2026 earnings?
- Theravance Biopharma (TBPH) reported Q2 2026 earnings on August 10, 2026 before market open.
- What were Theravance Biopharma's Q2 2026 revenue and EPS?
- Theravance Biopharma reported revenue of $20.7M and eps of $-0.11 for Q2 2026.
- Did Theravance Biopharma beat estimates in Q2 2026?
- Revenue missed the consensus estimate of $22.5M by $1.8M. EPS missed the consensus estimate of $0.07 by $0.18.
- How did Theravance Biopharma's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 20.9% from $26.2M a year earlier and eps declined 37.5% from $-0.08.
- Where can I find Theravance Biopharma's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001104659-26-093066) and the 10-Q periodic report (0001104659-26-093773) directly on SEC EDGAR. The filing index links above go to sec.gov.
